Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
ARVN compared with XERS: revenue, margins and what each company keeps, and the suppliers and customers both name
ARVN
Arvinas, Inc.
Change
Mkt cap
Revenue
Revenue
XERS
Xeris Biopharma Holdings, Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
ARVN
Arvinas, Inc.
vs
XERS
Xeris Biopharma Holdings, Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
ARVN, solid
XERS, dashed
Supply-chain overlap
Revenue flow
ARVN: latest quarter is a loss; flow not drawable.
Method
›
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only ARVN
4
PFE
Pfizer
customer
NVS
Novartis Pharma
customer
—
Yale University
unlisted
supplier
—
Bayer
unlisted
customer
Shared
0
No shared counterparties.
Only XERS
11
—
Bachem Americas
unlisted
supplier
—
Lonza Tampa
unlisted
supplier
—
Pyramid Laboratories
unlisted
supplier
—
Regis Technologies
unlisted
supplier
7 more · XERS chain
›
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR
ARVN
Arvinas, Inc.
Change
6.41
▼
−2.14%
· post 6.41
· delayed
Mkt cap
$428.9M
Revenue
$500,000
Q3 FY26
Revenue
$263M
FY25
XERS
Xeris Biopharma Holdings, Inc.
Change
15.20
▲
+16.17%
· post 15.20
· delayed
After hours
Nov 6 '26
delayed
Mkt cap
$2.4B
Revenue
$107M
Q3 FY26
Revenue
$292M
FY25
vs
Compare
After hours
Nov 6 '26
delayed
ARVN
Arvinas, Inc.
vs
XERS
Xeris Biopharma Holdings, Inc.
6.41
▼
−2.14%
post 6.41
delayed
Price
15.20
▲
+16.17%
post 15.20
delayed
$428.9M
Mkt cap
$2.4B
Q3 FY26
$500,000
Revenue
$107M
Q3 FY26
FY25
$263M
Revenue
$292M
FY25
Change
Change
ARVN
6.41
▼
−2.14%
vs
XERS
15.20
▲
+16.17%
After hours
Nov 6 '26
delayed